Ductal carcinoma in situ of the breast

Annals of Internal Medicine

Volumn 127, Issue 11, 1997, Pages 1013-1022

  Fonseca, Rafael ^a   Hartmann, Lynn C ^a   Petersen, Ivy A ^a   Donohue, John H ^a   Crotty, Thomas B ^a   Gisvold, John J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030694168     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-11-199712010-00013     Document Type: Review

References (98)

1. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am. 1990;70:853-71.
2. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer A forensic autopsy study. Cancer. 1987;60:2751-60.
3. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol. 1985;16:796-807.
4. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
5. Cutuli BF, Florentz P, Lacroze M, Dilhuydy JM, Allavena C, De Lafontan B, et al. Cancer du sein chez l'homme: etude de 15 cas de carcinome canalaire in situ (CCIS) pur. [Breast cancer in males: a study of 15 cases of pure ductal carcinoma in situ.] Bull Cancer (Paris). 1992;79:1045-53.
6. Camus MG, Joshi MG, Mackarem G, Lee AK, Rossi RL, Munson JL, et al. Ductal carcinoma in situ of the male breast. Cancer. 1994;74:1289-93.
7. Feuer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol. 1992;136:1423-36.
8. Ward BA, McKhann CF, Ravikumar TS. Ten-year follow-up of breast carcinoma in situ in Connecticut. Arch Surg. 1992;127:1392-5.
9. Bush DS, Remington PL, Reeves M, Phillips JL. In situ breast cancer correlates with mammography use, Wisconsin: 1980-1992. Wis Med J. 1994;93:483-4.
10. Garfinkel L, Boring CC, Heath CW Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer. 1994;74(Suppl 1):222-7.
11. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913-8.
12. Simon MS, Lemanne D, Schwartz AG, Martino S, Swanson GM. Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975-1988). Cancer. 1993;71:769-74.
13. Kessler LG, Feuer EJ, Brown ML. Projections of the breast cancer burden to U.S. women: 1900-2000. Prev Med. 1991;20:170-82.
14. Liff JM, Sung JF, Chow WH, Greenberg RS, Flanders WD. Does increased detection account for the rising incidence of breast cancer? Am J Public Health 1991;81:462-5.
15. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992;16:1133-43.
16. Mariuzzi GM, Mariuzzi L, Mombello A, Santinelli A, Valli M, Rahal D, et al. Quantitative study of ductal breast cancer progression. Morphometric evaluation of phenotypical changes occurring in benign and preinvasive epithelial lesions. Pathol Res Pract. 1994;190:1056-65.
17. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer. 1994;73:118-24.
18. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63:618-24.
19. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154-7.
20. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11:167-80.
21. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW, et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol. 1994;7:257-62.
22. Harrison M, Magee HM, O'Loughlin J, Gorey TF, Dervan PA. -Chromosome 1 aneusomy, identified by interphase cytogenetics, in mammographically detected ductal carcinoma in situ of the breast. J Pathol. 1995;175:303-9.
23. Douglas-Jones AG, Schmid KW, Bier B, Horgan K, Lyons K, Dallimore ND, et al. Metallothionein expression in duct carcinoma in situ of the breast. Hum Pathol. 1995;26:217-22.
24. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer. 1995;75:2123-31.
25. De Potter CR, Schelfhout AM, Verbeeck P, Lakhani SR, Brunken R, Schroeter CA, et al. neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum Pathol. 1995;26:601-6.
26. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C, The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992;7:1027-32.
27. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol. 1992;45:16-20.
28. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer. 1992;28:644-8.
29. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR. Relationship between c-eroB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat. 1991;18:11-7.
30. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with come-do-type ductal carcinoma in situ and limited prognostic value in stage ∥ breast cancer. N Engl J Med. 1988;319:1239-45.
31. Maguire HC Jr, Hellman ME, Greene MI, Yeh I. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology. 1992;60:117-21.
32. Walker RA, Dearcng SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991;165:203-11.
33. Munn KE, Walker RA, Menasce L, Varley JM. Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Br J Cancer. 1996;73:636-9.
34. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995;175:195-201.
35. Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmert-Buck MR. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res. 1995;55:467-71.
36. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995;1:1257-60.
37. Dershaw DD, Abramson A, Kinne DW. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology. 1989;170:411-5.
38. Lagios MD. Heterogeneity of ductal carcinoma in situ of the breast. J Cell Biochem Suppl. 1993;17G:49-52.
39. Evans A, Pinder S, Wilson R, Sibbering M, Poller D, Elston C, et al. Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol. 1994;162:1307-11.
40. Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. Mayo Clin Proc. 1993;68:454-60.
41. Ikeda DM, Andersson I. Ductal carcinoma in situ: atypical mammographic appearances. Radiology. 1989;172:661-6.
42. Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology. 1989;172:235-41.
43. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990;335:519-22.
44. Holland R, Hendriks JH. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol. 1994;11:181-92.
45. Farrow JH. Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer. 1970;25:468-77.
46. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49:751-8.
47. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197-200.
48. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46(4 Suppl):919-25.
49. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carci-noma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239:1863-7.
50. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223-35.
51. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50:1309-14.
52. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg. 1979;189:377-82.
53. Wobbes T, Tinnemans JG, van der Sluis RF. Residual tumour after biopsy for non-palpable ductal carcinoma in situ of the breast. Br J Surg. 1989;76:185-6.
54. Skjorten F, Amlie E, Larsen KA. On the occurrence of focal, occult in situ and invasive carcinoma in 250 mastectomy specimens. Eur J Surg Oncol. 1986;12:117-21.
55. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer. 1992;70:2468-74.
56. Carter D, Smith RR. Carcinoma in situ of the breast. Cancer. 1977;40:1189-93.
57. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol. 1991;47:139-47.
58. Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA. Rosen PP. Breast carcinoma in situ. Arch Surg. 1989;124:33-6.
59. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer. 1977;39:435-9.
60. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer. 1995;31A:1425-7.
61. Arnesson LG, Smeds S, Fagerberg G, Gröntoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. Br J Surg. 1989;76:672-5
62. Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986;121:1303-7.
63. Fisher ER, Sass R, Fisher B, Wicherham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986;57:197-208.
64. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg. 1985;150:44-51.
65. von Rueden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet. 1984;158:105-11.
66. Choi WS, Parker BA, Pierce JP, Greenberg ER. Regional differences in the incidence and treatment of carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1996;5:317-20.
67. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-6.
68. Gump FE, Jicha DL, Ozello L. Ductal carcinoma in situ (DCIS): a revised concept. Surgery. 1987;102:790-5.
69. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer. 1994;73:664-7.
70. White J, Levine A, Gustafson G, Wimbish K, lngold J, Pettinga J, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31:791-7.
71. Winchester DP, Menck HR, Osteen RT, Kraybill W. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol. 1995;2:207-13.
72. Carpenter R, Boulter PS, Cooke T, Gibbs NM. Management of screen detected ductal carcinoma in situ of the female breast. Br J Surg. 1989;76:564-7.
73. Graham MD, Lakhani S, Gazet JC. Breast conserving surgery in the management of in situ breast carcinoma. Eur J Surg Oncol. 1991;17:258-64.
74. Gallagher WJ, Koerner FC, Wood WC Treatment of intraductal carcinoma with limited surgery: long-term follow-up. J Clin Oncol. 1989;7:376-80.
75. Price P, Sinnett HD, Gusterson B, Walsh G, A'Hern RP, McKinna JA. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer. 1990;61:869-72.
76. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822-8.
77. Silverstein MJ, Cohlan BF, Gierson ED, Furmanski M, Gamagami P, Colburn WJ, et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer. 1992;28:630-4.
78. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol. 1992;16:1183-96.
79. Kurtz JM, Jacquemier J, Torhorst J, Spitalier JM, Amalric R, Hunig R, et al. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer. 1989;63:1630-5.
80. Solin LJ, Fowble BL, Schultz DJ, Yeh IT, Kowalyshyn MJ, Goodman RL. Definitive irradiation for intraductal carcinoma of the breast, Int J Radiat Oncol Biol Phys. 1990;19:843-50.
81. Bornstein BA, Recht A, Connolly JL, Schnitt SJ, Cady B, Koufman C, et al. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer. 1991;67:7-13.
82. Kuske RR, Bean JM, Garcia DM, Perez CA, Andriole D, Philpott G, et al. Breast conservation therapy for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1993;26:391-6.
83. Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:754-63.
84. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995;75:1310-9.
85. Lagios MD, Page DL. A critical appraisal of NSABP-B17, a randomized trial of irradiation of duct carcinoma in situ. Quarterly Review. Current Perspectives on Breast Cancer. 1994;1.
86. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clin Oncol. 1996;14:70-7.
87. McCormick B, Rosen PP, Kinne D, Cox L, Yahalom J. Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy, Int J Radiat Oncol Biol Phys. 1991;21:289-92.
88. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267-74.
89. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. The Van Nuys Prognostic Index for ductal carcinoma in situ. Breast J. 1996;2:38-40.
90. Sibbering DM, Ellis IO, Obuszko Z, Elston CW, Robertson JF, Blarney RW. Is radiotherapy necessary in adequately excised ductal carcinoma in situ (DCIS)? [Abstract]. J Pathol. 1996;178(Suppl):6A.
91. Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt). 1996;10(11 Suppl):47-75.
92. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet? [Editorial] Cancer. 1996;77:2189-92.
93. Solin LJ, Fourquet A, McCormick B, Haffty B, Recht A, Schultz DJ, et al. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast, Int J Radiat Oncol Biol Phys. 1994;30:3-9.
94. Frykberg ER, Bland KI. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer. 1994;74(1 Suppl):350-61.
95. Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer. 1993;68:156-61
96. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992;69:1174-81
97. Pallis L, Wilking N, Cedermark B, Rutqvist LE, Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res. 1992;12:2113-5.
98. Current Clinical Trials in Oncology. PDQ. 1996;3:P41.